Exact Sciences

Exact Sciences is a cancer diagnostic company that provides genomic and companion diagnostic (CDx) tests to guide personalized cancer treatment. Its portfolio includes main products Cologuard and Oncotype DX for screening and therapy selection in colorectal, breast, and prostate cancers. The company develops its cancer screening and genetic tests using stool-based DNA (sDNA) technology.

Operating on a B2B2C model, Exact offers its testing services to healthcare providers and hospitals globally. As of March 2023, the company had served over 4 million patients across 90 countries and commercially launched seven testing products.

To expand its capabilities in early detection and hereditary cancer testing, Exact has acquired multiple companies including OmicEra Diagnostics and PreventionGenetics . Flagship products like Cologuard can detect over 90% of colorectal cancers, providing critical screening insights. Additionally, in August 2022, MDxHealth signed an agreement to acquire Exact's prostate cancer testing operations, Oncotype DX, for USD 100 million. 

Key customers and partnerships

In January 2022, the company partnered with precision medicine company OncXerna Therapeutics to expand its OncXerna’s Xerna tumor microenvironment panel as a companion diagnostic to healthcare providers and biopharma companies. 

Funding and financials

The company began trading on Nasdaq in January 2001 under the ticker symbol “EXAS,” raising USD 56 million at the IPO. For the year ended December 2022 , revenue increased 18% YoY to USD 2.1 billion, and the net loss declined by 25% YoY to USD 624 million. In 1H 2023, revenue grew 21.5% YoY to USD 1.2 billion while net losses narrowed by 55.3% YoY to USD 155.2 million. The company increased its revenue guidance for the full-year 2023, expecting revenue in the range of USD 2.44 billion–2.47 billion, implying a 17%–19% YoY increase.